Cost-effectiveness and budget impact of docetaxel, abiraterone, enzalutamide, apalutamide or radiotherapy plus androgen deprivation therapy versus androgen deprivation therapy alone in newly diagnosed metastatic hormone-sensitive prostate cancer

Michaela Barbier, Yuki Tomonaga, Dominik Menges, Sarah Haile, Henock G Yebyo, Milo Puhan, Matthias Schwenkglenks
2020
doi:10.5167/uzh-195391 fatcat:xbe346cdcfbgrloer24wtqeky4